BIOTECHNOLOGY VALUE FUND L P - 24 Jan 2025 SCHEDULE 13G Report for Monte Rosa Therapeutics, Inc. Common Stock, $0.0001 par value per share (GLUE)

Filing Manager
BIOTECHNOLOGY VALUE FUND L P
Reporting Manager
BVF PARTNERS L P/IL
Security
Monte Rosa Therapeutics, Inc. Common Stock, $0.0001 par value per share
Symbol
GLUE
Shares outstanding
61M shares
Disclosed Ownership
4.39M shares
Ownership
7.2%
Form type
SCHEDULE 13G
Filing time
31 Jan 2025, 18:43:01 UTC
Date of event
24 Jan 2025
Next filing
15 May 2025
SEC
View on sec.gov

Reporting Managers (10)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
BIOTECHNOLOGY VALUE FUND L P 3.7% 2.26M 0 2.26M /s/ Mark N. Lampert Mark N. Lampert, Authorized Signatory
BVF I GP LLC 3.7% 2.26M 0 2.26M /s/ Mark N. Lampert Mark N. Lampert, Authorized Signatory
BIOTECHNOLOGY VALUE FUND II LP 3% 1.82M 0 1.82M /s/ Mark N. Lampert Mark N. Lampert, Authorized Signatory
BVF II GP LLC 3% 1.82M 0 1.82M /s/ Mark N. Lampert Mark N. Lampert, Authorized Signatory
Biotechnology Value Trading Fund OS LP 0.4% 228K 0 228K /s/ Mark N. Lampert Mark N. Lampert, Authorized Signatory
BVF Partners OS Ltd. 0.4% 228K 0 228K /s/ Mark N. Lampert Mark N. Lampert, Authorized Signatory
BVF GP HOLDINGS LLC 6.6% 4.08M 0 4.08M /s/ Mark N. Lampert Mark N. Lampert, Authorized Signatory
BVF PARTNERS L P/IL 7.2% 4.39M 0 4.39M /s/ Mark N. Lampert Mark N. Lampert, Authorized Signatory
BVF INC/IL 7.2% 4.39M 0 4.39M /s/ Mark N. Lampert Mark N. Lampert, Authorized Signatory
LAMPERT MARK N 7.2% 4.39M 0 4.39M /s/ Mark N. Lampert Mark N. Lampert